Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment

NCT02254070 | Completed Phase 1

• 1 other identifier: 1192.12
• Study Type: interventional
• Target: 23
• Locations: 0 countries
• Sites: N/A

Brief Summary

To assess the influence of different degrees of renal impairment on safety, tolerability, pharmacodynamics and pharmacokinetics of 1.0 mg of BIBT 986 BS given as a single dose infusion over 30 minutes in comparison to a normal renal function

Conditions

Healthy

Outcome Measures

Primary Outcomes (24)

• Maximum measured concentration of the analyte in plasma (Cmax)

  Up to 48 hours after drug administration

• Time to reach the maximum concentration of the analyte in plasma (tmax)

  Up to 48 hours after drug administration

• Total area under the plasma drug concentration-time curve from time zero to infinity (AUC0-∞)

  Up to 48 hours after drug administration

• Area under the concentration-time curve of the analyte in plasma from zero time to the time of the last quantifiable drug concentration (AUC0-tz)

  Up to 48 hours after drug administration

• Terminal rate constant of the analyte in plasma (λz)

  Up to 48 hours after drug administration

• Terminal half-life of the analyte in plasma (t1/2)

  Up to 48 hours after drug administration

• Mean residence time of the analyte in the body after intravenous infusion (MRTinf)

  Up to 48 hours after drug administration

• Total clearance of the analyte from plasma following intravascular administration (CL)

  Up to 48 hours after drug administration

• Apparent volume of distribution at steady state following an intravascular dose (Vss)

  Up to 48 hours after drug administration

• Apparent volume of distribution during the terminal phase λz following an intravascular dose (Vz)

  Up to 48 hours after drug administration

• Amount of drug excreted in the urine (Ae)

  Up to 48 hours after drug administration

• Change in activated partial thromboplastin time (aPTT)

  Up to 48 hours after drug administration

• Change in ecarin clotting time (ECT)

  Up to 48 hours after drug administration

• Change in International Normalized Ratio (INR)

  Up to 48 hours after drug administration

• Change in thrombin time (TT)

  Up to 48 hours after drug administration

• Plasma concentration of the analyte at the end of the intravenous infusion (CT)

  29 minutes after drug administration

• Number of participants with clinically significant changes in vital signs

  Blood pressure and pulse rate

  Up to 3 days after drug administration

• Number of participants with clinically significant changes in ECG (electrocardiogram)

  Up to 3 days after drug administration

• Number of participants with abnormal changes in clinical laboratory parameters

  Up to 3 days after drug administration

• Number of participants with adverse events

  Up to 3 days after drug administration

• Change in prothrombin time (PT)

  Up to 48 hours after drug administration

• partial area under the concentration time curve (from time 0 to last sampling time preceding hemodialysis in any of the patients) (AUCt1-t2)

  Up to 48 hours after drug administration

• fraction of administered drug excreted unchanged in urine over the respective time interval (fe)

  Up to 48 hours after drug administration

• Renal clearance of the analyte from plasma following intravascular administration (CLR)

  Up to 48 hours after drug administration

Study Arms (1)

BIBT 986 BS

EXPERIMENTAL

Drug: BIBT 986 BS

Interventions

BIBT 986 BS DRUG

BIBT 986 BS

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy male or female subjects determined by results of screening with a creatinine clearance \>80 mL/min (Group 1)
• Renally impaired male or female subjects determined by results of screening with the following creatinine clearance results:
• creatinine clearance 51-80 mL/min (Group 2)
• creatinine clearance 31-50 mL/min (Group 3)
• creatinine clearance ≤ 30 mL/min (Group 4)
• subjects requiring hemodialysis (Group 5)
• Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
• Age \>=18 and \<=75 years
• BMI \>=18.5 and \<=29.9 kg/m2 for Groups 1+2
• BMI \>=18.5 and \<=32 kg/m2 for Groups 3, 4 and 5

You may not qualify if:

• Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance
• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
• Surgery of gastrointestinal tract (except appendectomy)
• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
• Relevant history of orthostatic hypotension, fainting spells or blackouts
• Abnormal PT, TT, aPTT (must be within the normal range after no more than one repeated test), thrombocytes \< 150000/μl (two repeats of the first test)
• Evidence of haematuria either macroscopically detectable or microscopic on urinalysis (normal microscopic results after no ore than one repeated test)
• Evidence of blood dyscrasia, haemorrhagic diathesis, severe thrombocytopenia, cerebrovascular haemorrhage, bleeding tendencies associated with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with haemorrhagic tendencies (e.g. cerebral aneurysm, dissecting aorta, CNS trauma, retinopathy, nephrolithiasis)
• Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding (e.g. spinal puncture, lumbar block anaesthesia, surgery of central nervous system (CNS) or eye or surgery resulting in large open surfaces) within 14 days before or after drug administration of this clinical trial
• Occult blood in 1 of 3 subsequent faecal samples collected for the pre-study examination
• Chronic or relevant acute infections
• History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
• For women with childbearing potential: no reliable contraception (accepted methods are intra uterine device, hormonal contraceptives, bilateral tubal ligation, hysterectomy, condoms) or pregnancy (known or detected by a positive pregnancy test) or breast feeding period
• Intake of drugs with a long half-life (\> 24 hours) (\< 1 month prior to administration or during the trial)
• Use of any drugs, within 14 days prior to administration or during the trial

Sponsors & Collaborators

• Boehringer Ingelheim: lead

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 30, 2014
• First Posted: October 1, 2014
• Study Start: June 1, 2003
• Primary Completion: August 1, 2004
• Last Updated: October 1, 2014

Record last verified: 2014-09